[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR3074680B1 - COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID - Google Patents

COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID Download PDF

Info

Publication number
FR3074680B1
FR3074680B1 FR1761806A FR1761806A FR3074680B1 FR 3074680 B1 FR3074680 B1 FR 3074680B1 FR 1761806 A FR1761806 A FR 1761806A FR 1761806 A FR1761806 A FR 1761806A FR 3074680 B1 FR3074680 B1 FR 3074680B1
Authority
FR
France
Prior art keywords
amyline
analog
receptor agonist
polyaminoacid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1761806A
Other languages
French (fr)
Other versions
FR3074680A1 (en
Inventor
David Duracher
Gregory Meiffren
Remi Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1761806A priority Critical patent/FR3074680B1/en
Priority to PCT/EP2017/084674 priority patent/WO2018122278A1/en
Priority to CN201780086990.7A priority patent/CN110366424B/en
Priority to EP17825875.2A priority patent/EP3562500B1/en
Priority to US15/855,496 priority patent/US10463717B2/en
Publication of FR3074680A1 publication Critical patent/FR3074680A1/en
Priority to US16/598,240 priority patent/US11707507B2/en
Application granted granted Critical
Publication of FR3074680B1 publication Critical patent/FR3074680B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline ; b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy étant de formule I suivante : caractérisée en ce que la composition ne comprend pas d'une insuline basale dont le point isoélectrique pI est compris entre 5,8 et 8,5. Elle concerne également une composition caractérisée en ce qu'elle comprend en outre une insuline prandiale.The invention relates to a composition in the form of an aqueous solution for injection, the pH of which is between 6.0 and 8.0, comprising at least: a) amylin, an amylin receptor agonist or a analog of amylin; b) a co-polyamino acid carrying carboxylate charges and hydrophobic Hy radicals, said co-polyamino acid comprising glutamic or aspartic units and said hydrophobic Hy radicals being of formula I below: characterized in that the composition does not comprise any a basal insulin with an isoelectric point pI of between 5.8 and 8.5. It also relates to a composition characterized in that it further comprises a mealtime insulin.

FR1761806A 2016-12-27 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID Active FR3074680B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1761806A FR3074680B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
PCT/EP2017/084674 WO2018122278A1 (en) 2016-12-27 2017-12-27 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
CN201780086990.7A CN110366424B (en) 2016-12-27 2017-12-27 Composition in the form of an injectable aqueous solution comprising an amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
EP17825875.2A EP3562500B1 (en) 2016-12-27 2017-12-27 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
US15/855,496 US10463717B2 (en) 2016-12-27 2017-12-27 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
US16/598,240 US11707507B2 (en) 2016-12-27 2019-10-10 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761806 2017-12-07
FR1761806A FR3074680B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID

Publications (2)

Publication Number Publication Date
FR3074680A1 FR3074680A1 (en) 2019-06-14
FR3074680B1 true FR3074680B1 (en) 2020-01-03

Family

ID=62091959

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1761806A Active FR3074680B1 (en) 2016-12-27 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID

Country Status (1)

Country Link
FR (1) FR3074680B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104861A1 (en) * 2012-01-09 2013-07-18 Adocia Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
FR2985429B1 (en) * 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS

Also Published As

Publication number Publication date
FR3074680A1 (en) 2019-06-14

Similar Documents

Publication Publication Date Title
FR3001896B1 (en) PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
FR3001895B1 (en) PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
SA518400596B1 (en) Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is from 5.8 to 8.5, A Prandial Insulin and/or A Gastrointestinal Hormone, and A Co-Polyamino Acid Bearing Carboxylate
SA520412141B1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MA31997B1 (en) Novel insulin derivatives with an extremely delayed action profile
BR112018075259A2 (en) composition in the form of an injectable aqueous solution, the pH of which is 6.0 to 8.0
BR112017009405A2 (en) antibiotic compositions.
TN2018000443A1 (en) Stable liquid pharmaceutical preparation
BR112015019657A2 (en) topical compositions and methods of use thereof
CY1112353T1 (en) METAUTINE PRODUCTS AND THEIR USE
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
SA520412142B1 (en) Injectable solution with a ph 7 of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
ATE531769T1 (en) USE OF ESTERS AS COALESCENT AGENT
BR112013006087A2 (en) carrier lubricants including emulsions and methods for employing them
CO2019008987A2 (en) Improvements in or with respect to organic compounds
BR112018014277A2 (en) formulation, and method of preparing an injectable solution of an axl-adc
FR3061023B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3074680B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
BR112016006963A2 (en) pharmaceutical composition
FR3074682B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3083085B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
MA37672A1 (en) Somatostatin receptor agonist formulation
FR3036289B1 (en) INJECTION DEVICE FOR INJECTABLE PRODUCT CONTAINING A CANNULA SLIDING INTO A NEEDLE AND SYSTEM USING SUCH A DEVICE
ATE493143T1 (en) COLLOIDAL INSULIN FORMULATION WITH LONG-TERM EFFECT AND ITS PRODUCTION

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190614

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7